Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?

Background: Knowledge of significant prostate (sPCa) locations being missed with magnetic resonance (MR)- and transrectal ultrasound (TRUS)-guided biopsy (Bx) may help to improve these techniques.

Objective: To identify the location of sPCa lesions being missed with MR- and TRUS-Bx.

Design, Setting, And Participants: In a referral center, 223 consecutive Bx-naive men with elevated prostate specific antigen level and/or abnormal digital rectal examination were included.

Multiparametric MRI in the diagnosis of prostate cancer - a generational change.

Background: Whether a general practitioner (GP) should order prostate-specific antigen (PSA) testing for a patient is a question that has been unresolved for 25 years. The authors suggest that the image-based diagnostic pathway, rather than the biopsy-driven diagnostic pathway, will answer this question.

Objective: This article describes, in non-technical terms, the methodology of prostate imaging with multiparametric magnetic resonance imaging (mpMRI), and targeted biopsies of lesions within the prostate.

Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasound-Guided Biopsy.

Objective: The purpose of this article is to identify histopathologically proven prostate cancer locations using MRI followed by MRI-guided biopsy in patients with elevated prostate-specific antigen (PSA) levels and at least one negative transrectal ultrasound (TRUS)-guided biopsy session. Our hypothesis is that in this patient group most cancers are located in the anterior portion of the prostate. This may have implications for the biopsy strategy regarding the location of sampling.